

To the Press:

Exiqon A/S
Skelstedet 16
2950 Vedbæk
Denmark

Phone: +45 4566 0888
Fax: +45 4566 1888
exiqon@exiqon.com
www.exiqon.com
CVR/Tax Id: 18 98 44 31

7 January 2009

Exiqon to present at 27th J.P. Morgan Healthcare Conference

Exiqon will present at the J.P. Morgan Healthcare Conference in San Francisco on 15 January 2009

Exiqon A/S (NASDAQ OMX Copenhagen: "EXQ") today announced that they will be presenting at the J.P. Morgan 27th Healthcare Conference to be held on 12-15 January 2009 in San Francisco.

"It is very important for us to have been invited to present Exiqon at this investor conference. It proves to us that our company is being recognized as a key player in our industry and in the development of modern molecular diagnostic tests for improved treatment selection", says Lars Kongsbak, president and CEO of Exiqon A/S.

The annual J.P. Morgan event is the most visited investor conference of its kind.

Exiqon will be presenting its planned series of new molecular diagnostic tests that are based on genetic profiling using miRNA biomarkers. In December 2008, Exiqon announced the first in a series of new diagnostic tests to be launched to help identify individual patients treatment needs based on genetic testing (miRNA profiling) in line with the trend towards personalized medicine. The first test to be launched is a prognostic test which will help identify stage II colon cancer patients who may be at significantly higher risk for recurrence and for whom adjuvant chemotherapy may be warranted.

Exiqon's presentation is scheduled for 15 January at 9:00 a.m. (PST). Interested parties are invited to see the powerpoint presentation on the investor section of Exiqon's website at www.exiqon.com.

Additional information:

Lars Kongsbak, CEO, phone +45 45 66 08 88 (cell: +45 40 90 21 01)

Hans Henrik Chrois Christensen, CFO, phone +45 45 66 08 88 (cell: +45 40 90 21 31)

About Exiqon

Exiqon is a biotech company with activities in three business areas where the company's technologies provide a competitive advantage: Sale of diagnostic tests (Exiqon Diagnostics), sale of innovative research products for miRNA research (Exiqon Life Sciences), and in contract research together with pharmaceutical companies (Exiqon Pharma Services). Exiqon is dedicated to personalizing the treatment selection for cancer patients. The aim is to optimize the use of existing medicine and avoid unnecessary and non-effective treatment. By using molecular diagnostic tests that analyze the genetic profile of each patient's tumor, treatment selection can be optimized for individuals. Exiqon is uniquely positioned to develop such new diagnostic tests. Exiqon already markets diagnostic tests that based on fresh tumor tissue enable doctors to test whether their patients are resistant to one or more of the chemotherapies offered to treat these patients and help them select an efficacious treatment. Exiqon's new molecular diagnostic products are based on the LNA™ technology that



enables testing on fixed tissue. Launch of the first molecular diagnostic product was announced in December 2008. A number of new products will follow in the years ahead. Using the LNA™ technology is what has allowed Exiqon to establish a position for itself as one of the market's leading providers of research products for gene expression analysis. These research products are used by university scientists and in the pharmaceutical industry around the world to make groundbreaking discoveries about the correlation between gene activity and the development various diseases. Exiqon is also collaborating with pharmaceutical companies in their effort to develop new medicines based on biomarkers (Personalized Medicine). Exiqon has more than 200 employees and is listed on the NASDAQ OMX in Copenhagen and categorized as a biotech company (Small Cap+). Exiqon is financed until expected breakeven in 2011.

